FIGURE 3.

Establishment and validation of a new predictive model for PDAC patients receiving neoadjuvant chemotherapy by combining expression patterns of CD9 in both tumor and stroma. Survival analyses for OS and RFS of patients from neoadjuvant chemotherapy group with different CD9 risk levels. Kaplan–Meier survival curves for OS (A) and RFS (B) of patients in the Fudan cohort with different CD9 risk levels. Kaplan–Meier survival curves for OS (C) and RFS (D) of patients in the validation cohort with different CD9 risk levels. The nomogram (E, F) for 1‐year recurrence‐free predictive probability and the calibration curve (G, H) were established based on the Fudan (E, G) and validation (F, H) cohort